Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Conditions
Interventions
Group-1 (15mg, OPK-88004)
Group-2 (25 mg,OPK-88004)
+1 more
Locations
15
United States
Pinnacle Research Group
Anniston, Alabama, United States
Clinical Trials Research
Lincoln, California, United States
Northern California Research
Sacramento, California, United States
Bayview Research Group, LLC - Valley Village
Valley Village, California, United States
South Florida Medical Research
Aventura, Florida, United States
APF Research, LLC
Miami, Florida, United States
Start Date
February 21, 2018
Primary Completion Date
April 18, 2019
Completion Date
June 10, 2019
Last Updated
September 16, 2021
NCT07016620
NCT06312722
NCT06817733
NCT06265519
NCT04627701
NCT06225479
Lead Sponsor
OPKO Health, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions